Last reviewed · How we verify
sinecatechins 10% topical ointment
Sinecatechins 10% topical ointment works by inhibiting the replication of human papillomavirus (HPV) in the skin.
Sinecatechins 10% topical ointment works by inhibiting the replication of human papillomavirus (HPV) in the skin. Used for Treatment of external genital warts.
At a glance
| Generic name | sinecatechins 10% topical ointment |
|---|---|
| Also known as | Veregen ointment |
| Sponsor | Hospital Universitari Vall d'Hebron Research Institute |
| Drug class | Antiviral |
| Target | Human papillomavirus (HPV) E6 and E7 proteins |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Sinecatechins, derived from green tea, have been shown to have antiviral properties, specifically targeting the E6 and E7 proteins of HPV, which are responsible for the proliferation of infected cells. This mechanism of action is thought to contribute to the therapeutic effects of sinecatechins in treating external genital warts.
Approved indications
- Treatment of external genital warts
Common side effects
- Skin irritation
Key clinical trials
- Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic Keratosis (PHASE3)
- Clinical Trial for Evaluating the Efficacy and Safety of Electrocoagulation vs Topic Sinecatechins vs Topic Cidofovir Within the Treatment to High-grade Anal Intraepithelial Neoplasia in HIV Homosexual Males (PHASE3)
- Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment (PHASE2)
- Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study (PHASE4)
- Topical Green Tea Ointment in Treatment of Superficial Skin Cancer (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: